---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-091011"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2023-04-04T23:59:59+00:00"
generated_at: "2026-06-17T06:16:33.360159+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Alaunos amends license with Precigen; returns CAR/IL-12 rights, eliminates all payment obligations

## Summary
- Alaunos returns exclusive rights to CAR (CD19 & BCMA) and IL-12 products to Precigen; retains TCR and Sleeping Beauty licenses.
- All Alaunos development and commercialization obligations under the license are eliminated.
- Alaunos no longer owes milestone payments (up to $52.5M per program) or royalties; Precigen's royalty obligations also removed.
- Annual license payment reduced from $100,000 to $75,000.
- License term now tied to expiration of last valid patent claim instead of later of patent life or 12 years post-first commercial sale.

## SEC filing metadata
- accession: 0001193125-23-091011
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2023-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312523091011/0001193125-23-091011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312523091011/d429387d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-091011
- JSON: https://secwatch.observer/filing/0001193125-23-091011.json
- Plain text: https://secwatch.observer/filing/0001193125-23-091011.txt

## Key facts
- Material Agreements
  Alaunos Therapeutics, Inc. amended Amended and Restated Exclusive License Agreement with Precigen, Inc. valued at $75,000 (effective 2023-04-03).
  - Action: amendment
  - Agreement: license
  - Counterparty: Precigen, Inc.
  - Value: $75,000
  - Effective: 2023-04-03
  source text: On April 3, 2023, Alaunos Therapeutics, Inc. (the “Company”) and Precigen, Inc. (“Precigen”) entered into the Amended and Restated Exclusive License Agreement (the “A&R Agreement”) which amended and restated in its entirety the original Exclusive License Agreement, dated October 5, 2018, as amended (the “Original Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523091011/0001193125-23-091011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.